Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus irinotecan in EGFR-positive metastatic colorectal cancer
jRCT2080220192Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Bristol Myers Squibb.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080220192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220192.